Related Experiment Videos
Gitelman's syndrome presenting as intolerance to statin therapy
Danielle B Freedman1, David Housley
1Department of Chemical Pathology, Luton and Dunstable Hospital, Lewsey Road, Luton LU4 0DZ, UK.
Annals of Clinical Biochemistry
|June 14, 2005
Summary
Gitelman syndrome, a rare genetic disorder, can cause low serum potassium, leading to statin intolerance. This case highlights the importance of considering electrolyte imbalances in patients experiencing statin-induced myopathy.
Area of Science:
- Cardiology
- Genetics
- Nephrology
Background:
- Statin-induced myopathy is a common adverse effect of statin therapy.
- Several predisposing factors for statin-induced myopathy have been identified.
Observation:
- A patient presented with statin intolerance.
- The patient had previously undiagnosed Gitelman syndrome.
Findings:
- The patient's statin intolerance was linked to serum potassium changes.
- Gitelman syndrome was identified as the underlying cause of the electrolyte imbalance.
Implications:
- This case underscores the importance of evaluating electrolyte levels in patients with unexplained statin intolerance.
- Diagnosing and managing underlying genetic conditions like Gitelman syndrome can resolve statin-induced myopathy.
- Considering rare genetic disorders is crucial for comprehensive patient care and effective treatment strategies.